Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model

Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model

ABSTRACT Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide since December 2019, causing coronavirus disease 2019 (COVID-19). Although vaccines for this virus have been developed rapidly, repurposing drugs approved to treat other diseases remains an invaluable treatmen...

Full description

Bibliographic Details
Main Authors: Shiho Chiba, Maki Kiso, Noriko Nakajima, Shun Iida, Tadashi Maemura, Makoto Kuroda, Yuko Sato, Mutsumi Ito, Moe Okuda, Shinya Yamada, Kiyoko Iwatsuki-Horimoto, Tokiko Watanabe, Masaki Imai, Tammy Armbrust, Ralph S. Baric, Peter J. Halfmann, Tadaki Suzuki, Yoshihiro Kawaoka
Format: Article
Language:English
Published: American Society for Microbiology 2022-02-01
Series:mBio
Subjects:
SARS-CoV-2
favipiravir
remdesivir
GS-441524
Syrian hamster
Online Access:https://journals.asm.org/doi/10.1128/mbio.03044-21

Internet

https://journals.asm.org/doi/10.1128/mbio.03044-21

Similar Items